Tesamorelin, CJC-1295 (No DAC), Ipamorelin
Also known as No DAC
This triple stack synergistically maximizes visceral fat reduction through Tesamorelin’s targeted abdominal lipolysis (15% waist circumference reduction in HIV lipodystrophy), CJC-1295’s sustained GH pulsatility (3-5x baseline elevation over 6-8 hours), and Ipamorelin’s clean GH amplification without cortisol/prolactin spikes—achieving superior IGF-1 increases (up to 200%) and metabolic optimization versus dual therapies. Tesamorelin selectively mobilizes trunk fat via hypothalamic GH axis stimulation, complemented by CJC-1295’s half-life extension and Ipamorelin’s pituitary synergy.
Route
Subcutaneous injection
Dose range
100 mcg – 1 mg
Frequency
Once per day (5 days on / 2 days off protocol often used)
Cycle length
12–26 weeks
Overview
This triple stack synergistically maximizes visceral fat reduction through Tesamorelin’s targeted abdominal lipolysis (15% waist circumference reduction in HIV lipodystrophy), CJC-1295’s sustained GH pulsatility (3-5x baseline elevation over 6-8 hours), and Ipamorelin’s clean GH amplification without cortisol/prolactin spikes—achieving superior IGF-1 increases (up to 200%) and metabolic optimization versus dual therapies. Tesamorelin selectively mobilizes trunk fat via hypothalamic GH axis stimulation, complemented by CJC-1295’s half-life extension and Ipamorelin’s pituitary synergy.
Ideal for stubborn visceral adiposity, metabolic syndrome, or HIV-associated lipodystrophy, the combination preserves lean mass while enhancing recovery and collagen. Nightly injection protocol aligns with natural GH pulses for physiologic restoration. For profound abdominal fat loss with GH rejuvenation, this stack delivers pharmaceutical-grade transformation.
Studied benefits
- A high-potency "triple-pathway" stack designed for maximum body recomposition
- It specifically targets the reduction of stubborn visceral (abdominal) fat through Tesamorelin, while CJC-1295 and Ipamorelin provide a robust, pulsatile release of natural Growth Hormone to support lean muscle maintenance and physical recovery
Reported side effects
- Potential for mild musculoskeletal discomfort (joint or muscle aches) and peripheral edema (slight swelling of hands or feet)
- Users should monitor IGF-1 and blood glucose levels, as these compounds can influence metabolic markers over time
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
| Compound | Standard Dose | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Tesamorelin | 1.0 mg | 40 units (0.4 mL) | + Log |
| CJC-1295 (No DAC) | 100 mcg | 4 units (0.04 mL) | + Log |
| Ipamorelin | 100 mcg | 4 units (0.04 mL) | + Log |
Frequency
Once per day (5 days on / 2 days off protocol often used).
Timing
Bedtime on an empty stomach.
Cycle length
12–26 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
5 doses of 1 mg per vial
At the starting dose (1 mg × 7/week for a 12-week cycle) you would use about 84 mg, i.e. 17 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
This advanced "Triple GH Pulse" stack requires a high-protein, calorie-controlled diet to maximize the powerful lipolytic effects, particularly targeting visceral adipose tissue. Incorporate high-intensity interval training (HIIT) and resistance training to leverage the substantial growth hormone elevation for body composition optimization and enhanced recovery. Ensure 7–9 hours of quality sleep to synchronize with the deep-sleep GH peaks that this blend is designed to stimulate. Adhere to strict fasting protocols—no food for 2–3 hours before and 30–60 minutes after administration—to prevent insulin spikes from blunting the complex signaling at the pituitary receptors.
Evidence
Research summaries
Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I (IGF-I) Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
Findings: Sustained GH boost for 6+ days, IGF-1 elevation for 9-11 days, dose-dependent fat loss, lean muscle preservation, safe metabolic profile
Scientists gave healthy adults (ages 21-61) CJC-1295 shots in a placebo-controlled trial. After one injection, GH jumped 2-10 fold and stayed elevated for over a week. IGF-1 (the muscle-building hormone triggered by GH) rose 1.5-3 fold and remained above baseline for 9-11 days. The peptide's half-life is 5.8-8.1 days—much longer than natural GHRH's few minutes—because it sticks to albumin (a blood protein) like velcro. When they gave repeated doses, IGF-1 stayed elevated for 28 days, showing a stacking effect. No serious side effects. This matters because sustained GH means your liver keeps pumping IGF-1, fueling muscle growth and fat breakdown without the peaks-and-valleys that short-acting hormones create. For 9th graders: imagine a water fountain that keeps trickling for a week instead of spraying once—your body absorbs more benefit overall.
Read the study ↗Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
Findings: Maintains natural GH pulses while boosting baseline, prevents hormone receptor burnout, optimizes IGF-1 response
This study checked whether CJC-1295's long action breaks your body's natural GH rhythm. Researchers sampled blood every 20 minutes overnight in healthy men before and after a CJC-1295 injection. Result? GH pulsatility was preserved—your natural peaks and valleys stayed intact, but the valleys got much higher (7.5-fold higher baseline GH!). Mean GH increased 46% overall, and IGF-1 climbed 45%. The key insight: CJC-1295 doesn't blunt your pituitary like synthetic GH would; it just amplifies your body's own rhythm. Basal (resting) GH levels spiked the most, and this baseline boost drove the IGF-1 gain—suggesting your liver is constantly getting the "make more IGF-1" signal. Why it matters? Your body evolved pulsatile GH release for a reason: steady stimulation vs. blast therapy prevents your cells from "ignoring" the hormone (receptor desensitization). CJC-1295 respects this biology.
Read the study ↗Effects of Tesamorelin on Visceral Adiposity, Triglycerides, and Cholesterol in HIV-Infected Patients
Findings: Visceral (belly) fat loss of 24 cm² vs. placebo gain, triglyceride drop, improved cholesterol ratios, better body image
806 HIV-infected men and women with excess abdominal fat were split into tesamorelin (2 mg daily injection) or placebo groups for 26 weeks. Tesamorelin shrank visceral fat (the dangerous deep belly kind) by 24 cm² while placebo actually gained 2 cm². That's a 26-cm² advantage—clinically significant. Triglycerides (blood fats linked to heart disease) dropped 37 mg/dL on tesamorelin but rose 6 mg/dL on placebo. Cholesterol-to-HDL ratios improved 0.36 points on tesamorelin vs. worsened 0.18 on placebo. Body image scores—how patients rated their belly appearance—improved dramatically in the tesamorelin arm. IGF-1 shot up 108 ng/mL (tesamorelin) vs. dropped 7 ng/mL (placebo), confirming strong GH axis activation. At 52 weeks (one year), visceral fat loss held steady or even improved further. This study used a GHRH-analog (tesamorelin mimics natural GH-releasing hormone), which stimulates your pituitary gently, not like a hormone shot that bypasses your body's feedback. For context: visceral fat is metabolically "toxic"—it promotes inflammation and insulin resistance. Losing 24 cm² of it rivals weight-loss surgery benefits.
Read the study ↗Ipamorelin, the First Selective Growth Hormone Secretagogue
Findings: Potent GH release without cortisol/ACTH surge, no hormone disruption, clean metabolic profile, unique selectivity
Researchers developed and tested ipamorelin, a five-amino-acid peptide (pentapeptide) that's a growth hormone secretagogue—a peptide that triggers GH release.
Read the study ↗Identification
Chemistry
- cas
- 218949-48-5
- formula
- C₂₂₁H₃₆₆N₇₂O₆₇S
- molecular weight
- 5135.86–5136 g/mol (free base); approximately 5196 Da
- sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks